Unexpectedly, we found that the drug not only targeted p53-wt, but also p53-mutated or p53-null tumor cell lines, while it was ineffective on non-transformed cells, and it significantly reduced cisplatin concentration in cytotoxic assays of resistant cells. Here, TP53 is linked to neoplasm.